Systems Biology of a MicroRNA Network in Neutrophilic Asthma
中性粒细胞性哮喘中 MicroRNA 网络的系统生物学
基本信息
- 批准号:10434046
- 负责人:
- 金额:$ 62.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdrenal Cortex HormonesAffectAirway DiseaseAsthmaBiologicalBiological ProductsCell SeparationCellsData SetEnvironmentEpithelial CellsFoundationsFutureGene ExpressionGene Expression RegulationGenesHospitalizationIn Situ HybridizationInflammationInflammatoryInhalationInterleukin-17KnowledgeLeadLymphocyteMessenger RNAMicroRNAsModalityNew YorkPathway interactionsPatientsPublic HealthQuality of lifeRegistriesRegulationRoleSamplingSeveritiesSeverity of illnessSputumSteroid ResistanceSystems BiologyTherapeuticToll-Like Receptor PathwayTransfectionUniversitiesUntranslated RNAWorkairway epitheliumairway inflammationairway obstructionasthma exacerbationcohortexperimental studyextracellularextracellular vesiclesgene regulatory networkimprovedimproved outcomemembermiRNA expression profilingneutrophilnovelresponsetherapeutic developmenttherapeutic targettranscriptome sequencingtreatment response
项目摘要
Neutrophilic airway inflammation is associated with increased asthma severity. Nearly 50% of patients with
asthma are non-eosinophilic and thus less likely to respond completely to corticosteroid therapy or current
biologics, illustrating the unmet need to improve our understanding of this group of patients. Despite these
associations, the pathways involved in neutrophilic asthma (NA) are only partially understood. MicroRNAs
(miRNAs) exert a powerful effect on gene regulation and have been implicated in T helper 2 airway inflammation
in asthma. However, there is a knowledge gap in our understanding of the role of miRNAs in NA.
MiR-223-3p is associated with severe NA and leads to airway epithelial changes, implicating miRNAs in NA.
Work by our group at the Yale Center for Asthma and Airway Disease cohort (YCAAD) found that miR-223-3p
belongs to a network of a dozen miRNAs in sputum cells associated with airflow obstruction, asthma
hospitalizations, decreased asthma quality of life, lymphocyte and neutrophil counts in the sputum. To
understand this cell-specific association we performed in situ hybridization to identify sputum cells expressing
miR-223-3p and found that neutrophils express high levels of miR-223-3p. This miRNA is positively correlated
with toll-like receptor pathways and IL-17 expression in patients with asthma.
We hypothesize that the sputum miRNA network is involved in the regulation of the Th17 pathway and
neutrophilic airway inflammation in asthma. We will utilize two well characterized cohorts, YCAAD and the New
York University/Bellevue Asthma Registry (NYUBAR), to execute the following aims:
Aim 1. To determine the longitudinal expression of the sputum miRNA network and its role in neutrophilic
airway inflammation. This aim will determine the stability of miRNA expression in the YCAAD cohort and will
validate the expression of the miRNA network in the NYUBAR cohort.
Aim 2. To define the network miRNAs released in extracellular vesicles and their association with neutrophilic
airway inflammation. This aim will determine the extent to which unique network miRNAs are released into the
extracellular environment via extracellular vesicles (EVs) and exert their functional role in the regulation of Th17
inflammation in airway epithelial cells.
Aim 3. To determine the effect of the miRNA network in airway epithelial gene expression and its contribution
to neutrophilic airway inflammation. This aim will elucidate how the miRNAs in the network interact with each
other and how their regulatory role converges on specific inflammatory pathways.
These studies will investigate a poorly understood asthma endotype using a novel paradigm of miRNA
regulation of neutrophilic airway inflammation. The results derived from this project will lay the foundation for the
improved identification of gene regulatory networks involved in NA and lead to potential therapeutic manipulation
of miRNAs in neutrophilic airway inflammation.
嗜中性气道炎症与哮喘严重程度增加有关。近50%的患者
哮喘是非嗜酸性粒细胞的,因此对皮质类固醇治疗或电流完全反应的可能性较小
生物制剂说明了提高我们对这组患者的理解的未满足需要。尽管如此
相关性,仅部分理解了嗜中性哮喘(NA)所涉及的途径。 microRNA
(miRNA)对基因调节产生强大的影响,并与T助手2气道炎症有关
在哮喘中。但是,我们对miRNA在NA中的作用的理解存在知识差距。
miR-223-3p与严重的NA相关,并导致气道上皮变化,这意味着NA中的miRNA。
我们小组在耶鲁大学哮喘和气道疾病队列中心(YCAAD)的工作发现miR-223-3p
属于与气流阻塞,哮喘相关的痰细胞中十几个miRNA网络
痰中的住院治疗,降低哮喘的生活质量,淋巴细胞和中性粒细胞。到
了解我们进行原位杂交的这种细胞特异性关联,以鉴定表达的痰细胞
miR-223-3p,发现中性粒细胞表达高水平的miR-223-3p。这个miRNA是正相关的
哮喘患者的TOLL样受体途径和IL-17的表达。
我们假设痰miRNA网络参与了TH17途径的调节和
哮喘中嗜中性气道炎症。我们将利用两个特征良好的队列,YCAAD和新的
约克大学/贝尔维尤哮喘注册表(Nyubar)执行以下目标:
目标1。确定痰miRNA网络的纵向表达及其在中性粒细胞中的作用
气道炎症。这个目的将确定miRNA表达在YCAAD队列中的稳定性,并将
验证miRNA网络在Nyubar队列中的表达。
目标2。定义细胞外囊泡中释放的网络miRNA及其与中性粒细胞的关联
气道炎症。这个目标将确定独特网络miRNA被释放到多大程度上
细胞外环境通过细胞外囊泡(EV),并在TH17的调节中发挥其功能作用
气道上皮细胞中的炎症。
目标3。确定miRNA网络在气道上皮基因表达及其贡献中的影响
嗜中性气道炎症。这个目标将阐明网络中的miRNA如何与每个网络相互作用
其他以及他们的调节作用如何在特定的炎症途径上融合。
这些研究将使用新型miRNA范式研究尚未了解的哮喘内型
调节中性粒细胞气道炎症。从该项目得出的结果将为
改善了涉及NA的基因调节网络并导致潜在的治疗操作的鉴定
中性粒细胞气道炎症中的miRNA。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jose Luis Gomez-Villalobos其他文献
Jose Luis Gomez-Villalobos的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jose Luis Gomez-Villalobos', 18)}}的其他基金
Systems Biology of a MicroRNA Network in Neutrophilic Asthma
中性粒细胞性哮喘中 MicroRNA 网络的系统生物学
- 批准号:
10198039 - 财政年份:2020
- 资助金额:
$ 62.85万 - 项目类别:
Systems Biology of a MicroRNA Network in Neutrophilic Asthma
中性粒细胞性哮喘中 MicroRNA 网络的系统生物学
- 批准号:
10033783 - 财政年份:2020
- 资助金额:
$ 62.85万 - 项目类别:
Regulation of Neutrophilic Airway Inflammation by miR-223-3p
miR-223-3p 对中性粒细胞气道炎症的调节
- 批准号:
10064359 - 财政年份:2020
- 资助金额:
$ 62.85万 - 项目类别:
Regulation of Neutrophilic Airway Inflammation by miR-223-3p
miR-223-3p 对中性粒细胞气道炎症的调节
- 批准号:
10221048 - 财政年份:2020
- 资助金额:
$ 62.85万 - 项目类别:
Systems Biology of a MicroRNA Network in Neutrophilic Asthma
中性粒细胞性哮喘中 MicroRNA 网络的系统生物学
- 批准号:
10842660 - 财政年份:2020
- 资助金额:
$ 62.85万 - 项目类别:
Systems Biology of a MicroRNA Network in Neutrophilic Asthma
中性粒细胞性哮喘中 MicroRNA 网络的系统生物学
- 批准号:
10599639 - 财政年份:2020
- 资助金额:
$ 62.85万 - 项目类别:
Systems Biology of a MicroRNA Network in Neutrophilic Asthma
中性粒细胞性哮喘中 MicroRNA 网络的系统生物学
- 批准号:
10657651 - 财政年份:2020
- 资助金额:
$ 62.85万 - 项目类别:
Functional role of hsa-miR-504 in airway inflammation and remodeling in asthma
hsa-miR-504 在哮喘气道炎症和重塑中的功能作用
- 批准号:
9284521 - 财政年份:2015
- 资助金额:
$ 62.85万 - 项目类别:
Functional role of hsa-miR-504 in airway inflammation and remodeling in asthma
hsa-miR-504 在哮喘气道炎症和重塑中的功能作用
- 批准号:
8803630 - 财政年份:2015
- 资助金额:
$ 62.85万 - 项目类别:
Functional role of hsa-miR-504 in airway inflammation and remodeling in asthma
hsa-miR-504 在哮喘气道炎症和重塑中的功能作用
- 批准号:
9762966 - 财政年份:2015
- 资助金额:
$ 62.85万 - 项目类别:
相似国自然基金
NPC1调控肾上腺皮质激素分泌影响代谢稳态的机制研究
- 批准号:82370796
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
孕期促肾上腺皮质激素释放激素(CRH)通过引起DNA甲基化发生程序化稳定改变长期影响婴幼儿神经行为发育
- 批准号:82103851
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
孕期促肾上腺皮质激素释放激素(CRH)通过引起DNA甲基化发生程序化稳定改变长期影响婴幼儿神经行为发育
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:
自主要求剖宫产对子代工作记忆的影响及低位GCs与海马CRH-CRHR1信号互作机制
- 批准号:81872630
- 批准年份:2018
- 资助金额:58.0 万元
- 项目类别:面上项目
应用H295R细胞研究SF-1、ACTHR对肾上腺皮质激素分泌调控的影响机制
- 批准号:81200579
- 批准年份:2012
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
相似海外基金
A First-in-class Topical Immunoregulatory Therapeutic for Psoriasis
一流的牛皮癣局部免疫调节疗法
- 批准号:
10820331 - 财政年份:2023
- 资助金额:
$ 62.85万 - 项目类别:
Intra-Articular Drug Delivery Modulating Immune Cells in Inflammatory Joint Disease
关节内药物递送调节炎症性关节疾病中的免疫细胞
- 批准号:
10856753 - 财政年份:2023
- 资助金额:
$ 62.85万 - 项目类别:
An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD
一种吸入性微生物组靶向生物治疗药物,用于治疗慢性阻塞性肺病
- 批准号:
10600887 - 财政年份:2023
- 资助金额:
$ 62.85万 - 项目类别:
Toward therapeutic targeting of liquid-liquid phase separation dynamics in skin
皮肤液-液相分离动力学的治疗靶向
- 批准号:
10679610 - 财政年份:2023
- 资助金额:
$ 62.85万 - 项目类别:
Dose escalation clinical trial of high-dose oral montelukast to inform future RCT in children with acute asthma exacerbations
大剂量口服孟鲁司特的剂量递增临床试验为哮喘急性发作儿童的未来随机对照试验提供信息
- 批准号:
10649012 - 财政年份:2023
- 资助金额:
$ 62.85万 - 项目类别: